Invention Grant
- Patent Title: Recombinant plasma membrane-based vesicle, for treating cancer
-
Application No.: US16967074Application Date: 2018-09-28
-
Publication No.: US12295978B2Publication Date: 2025-05-13
- Inventor: Gi-Beom Kim , Yoo Soo Yang , In-San Kim , Gihoon Nam
- Applicant: SHIFTBIO INC.
- Applicant Address: KR Seoul
- Assignee: SHIFTBIO INC.
- Current Assignee: SHIFTBIO INC.
- Current Assignee Address: KR Seoul
- Agency: Bozicevic, Field & Francis LLP
- Agent James S. Keddie
- Priority: KR10-2017-0126202 20170928
- International Application: PCT/KR2018/011504 WO 20180928
- International Announcement: WO2019/066535 WO 20190404
- Main IPC: A61K35/766
- IPC: A61K35/766 ; A61K45/06 ; A61P35/00 ; C07K16/28
Abstract:
The present invention relates to a recombinant plasma membrane-based vesicle, and more specifically to a recombinant plasma membrane-based vesicle comprising a VSV-G mutated protein in which histidine, the 162nd amino acid, has been substituted with arginine, and a pharmaceutical composition for treating cancer comprising the recombinant plasma membrane-based vesicle.
Public/Granted literature
- US20210106632A1 NOVEL RECOMBINANT PLASMA MEMBRANE-BASED VESICLE, FOR TREATING CANCER Public/Granted day:2021-04-15
Information query
